Cytokines for monitoring anti-tuberculous therapy: A systematic review.

[1]  William Fulp,et al.  Human Papillomavirus (HPV) L1 Serum Antibodies and the Risk of Subsequent Oral HPV Acquisition in Men: The HIM Study. , 2016, The Journal of infectious diseases.

[2]  J. Park,et al.  Comparative analysis of whole‐blood interferon‐γ and flow cytometry assays for detecting post‐treatment Immune responses in patients with active tuberculosis , 2014, Cytometry. Part B, Clinical cytometry.

[3]  Sang-Nae Cho,et al.  Efficacy of IP-10 as a biomarker for monitoring tuberculosis treatment. , 2014, The Journal of infection.

[4]  J. Damås,et al.  Soluble Markers of the Toll-Like Receptor 4 Pathway Differentiate between Active and Latent Tuberculosis and Are Associated with Treatment Responses , 2013, PloS one.

[5]  M. Morgado,et al.  T Cell Activation and Cytokine Profile of Tuberculosis and HIV-Positive Individuals during Antituberculous Treatment and Efavirenz-Based Regimens , 2013, PloS one.

[6]  D. Goletti,et al.  IFNγ/TNFα specific-cells and effector memory phenotype associate with active tuberculosis. , 2013, The Journal of infection.

[7]  D. Mitra,et al.  Foxp3+ Regulatory T Cells among Tuberculosis Patients: Impact on Prognosis and Restoration of Antigen Specific IFN-γ Producing T Cells , 2012, PloS one.

[8]  C. Perez-Velez.  Pediatric tuberculosis: new guidelines and recommendations , 2012, Current opinion in pediatrics.

[9]  L. Cuevas,et al.  Interferon Gamma–induced Protein-10 Concentrations in Children With Previous Tuberculosis Infections and Disease , 2012, The Pediatric infectious disease journal.

[10]  E. Chiappini,et al.  Utility of interferon-γ release assay results to monitor anti-tubercular treatment in adults and children. , 2012, Clinical therapeutics.

[11]  N. Boéchat,et al.  Interleukin-10 and interferon-gamma patterns during tuberculosis treatment: possible association with recurrence. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[12]  C.-C. Shu,et al.  Expression of toll-like receptor 2 and plasma level of interleukin-10 are associated with outcome in tuberculosis , 2012, European Journal of Clinical Microbiology & Infectious Diseases.

[13]  He-ping Xiao,et al.  [Changes and significance of peripheral blood T cell subsets, soluble interleukin-2 receptor and interferon-gamma in patients with retreatment pulmonary tuberculosis and initial treatment tuberculosis]. , 2011, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases.

[14]  T. Ottenhoff,et al.  Higher Frequency of T-Cell Response to M. tuberculosis Latency Antigen Rv2628 at the Site of Active Tuberculosis Disease than in Peripheral Blood , 2011, PloS one.

[15]  S. Bertholet,et al.  Effect of Chemotherapy on Whole-Blood Cytokine Responses to Mycobacterium tuberculosis Antigens in a Small Cohort of Patients with Pulmonary Tuberculosis , 2011, Clinical and Vaccine Immunology.

[16]  T. Bodmer,et al.  Clinical Significance of Interleukin-2/Gamma Interferon Ratios in Mycobacterium tuberculosis-Specific T-Cell Signatures , 2011, Clinical and Vaccine Immunology.

[17]  D. Minnikin,et al.  A mycolic acid-specific CD1-restricted T cell population contributes to acute and memory immune responses in human tuberculosis infection. , 2011, The Journal of clinical investigation.

[18]  G. Ippolito,et al.  IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculosis therapy , 2011, BMC infectious diseases.

[19]  Jan Dirks,et al.  Whole-Blood Flow-Cytometric Analysis of Antigen-Specific CD4 T-Cell Cytokine Profiles Distinguishes Active Tuberculosis from Non-Active States , 2011, PloS one.

[20]  G. Rook,et al.  CCL2, CCL18 and sIL-4R in renal, meningeal and pulmonary TB; a 2 year study of patients and contacts. , 2011, Tuberculosis.

[21]  G. Pantaleo,et al.  Dominant TNF-α+ Mycobacterium tuberculosis–specific CD4+ T cell responses discriminate between latent infection and active disease , 2011, Nature Medicine.

[22]  J. Kaldor,et al.  Mediators of innate and adaptive immune responses differentially affect immune restoration disease associated with Mycobacterium tuberculosis in HIV patients beginning antiretroviral therapy. , 2010, The Journal of infectious diseases.

[23]  S. Gooding,et al.  Mycobacterium tuberculosis-specific cellular immune profiles suggest bacillary persistence decades after spontaneous cure in untreated tuberculosis. , 2010, The Journal of infectious diseases.

[24]  C. Ciuce,et al.  Clinical aspects and cytokine response in severe H1N1 influenza A virus infection , 2010, Critical care.

[25]  G. Kaplan,et al.  Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns. , 2010, American journal of respiratory and critical care medicine.

[26]  T. Ottenhoff,et al.  Increased IgG1, IFN-gamma, TNF-alpha and IL-6 responses to Mycobacterium tuberculosis antigens in patients with tuberculosis are lower after chemotherapy. , 2010, International immunology.

[27]  R. Wilkinson,et al.  Polyfunctional T cells in human tuberculosis , 2010, European journal of immunology.

[28]  Ifedayo M. O. Adetifa,et al.  Expanded Polyfunctional T Cell Response to Mycobacterial Antigens in TB Disease and Contraction Post-Treatment , 2010, PloS one.

[29]  H. Zar,et al.  Reversion and conversion of Mycobacterium tuberculosis IFN-γ ELISpot results during anti-tuberculous treatment in HIV-infected children , 2010, BMC infectious diseases.

[30]  L. Castellano,et al.  T cells activation and cytokines balance in active and cured tuberculosis , 2010 .

[31]  Sang-Nae Cho,et al.  Association of Antigen-Stimulated Release of Tumor Necrosis Factor-Alpha in Whole Blood with Response to Chemotherapy in Patients with Pulmonary Multidrug-Resistant Tuberculosis , 2010, Respiration.

[32]  Chin-Pyng Wu,et al.  Association of Reduced Tumor Necrosis Factor Alpha, Gamma Interferon, and Interleukin-1β (IL-1β) but Increased IL-10 Expression with Improved Chest Radiography in Patients with Pulmonary Tuberculosis , 2009, Clinical and Vaccine Immunology.

[33]  Clarice Abramo,et al.  Anti-mycobacterial treatment reduces high plasma levels of CXC-chemokines detected in active tuberculosis by cytometric bead array. , 2009, Memorias do Instituto Oswaldo Cruz.

[34]  T. Perneger,et al.  Do results of the T-SPOT.TB interferon-gamma release assay change after treatment of tuberculosis? , 2009, Respiratory medicine.

[35]  S. Hasnain,et al.  In Vitro Levels of Interleukin 10 (IL-10) and IL-12 in Response to a Recombinant 32-Kilodalton Antigen of Mycobacterium bovis BCG after Treatment for Tuberculosis , 2008, Clinical and Vaccine Immunology.

[36]  S. Calvi,et al.  Cytokines and acute phase serum proteins as markers of inflammatory regression during the treatment of pulmonary tuberculosis. , 2008, Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia.

[37]  K. Higuchi,et al.  Interferon‐γ responses after isoniazid chemotherapy for latent tuberculosis , 2008, Respirology.

[38]  R. Hussain,et al.  Longitudinal Tracking of Cytokines after Acute Exposure to Tuberculosis: Association of Distinct Cytokine Patterns with Protection and Disease Development , 2007, Clinical and Vaccine Immunology.

[39]  V. Sypsa,et al.  The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  B. Alisjahbana,et al.  Plasma granulysin levels and cellular interferon-gamma production correlate with curative host responses in tuberculosis, while plasma interferon-gamma levels correlate with tuberculosis disease activity in adults. , 2007, Tuberculosis.

[41]  P. Klenerman,et al.  Dynamic Relationship between IFN-γ and IL-2 Profile of Mycobacterium tuberculosis-Specific T Cells and Antigen Load1 , 2007, The Journal of Immunology.

[42]  T. Barkham,et al.  Latent tuberculosis infection treatment and T-cell responses to Mycobacterium tuberculosis-specific antigens. , 2007, American journal of respiratory and critical care medicine.

[43]  R. Joshi,et al.  Serial testing of health care workers for tuberculosis using interferon-γ assay , 2006 .

[44]  Eun-Kyeong Jo,et al.  Ex Vivo Responses for Interferon‐gamma and Proinflammatory Cytokine Secretion to Low‐Molecular‐Weight Antigen MTB12 of Mycobacterium tuberculosis during Human Tuberculosis , 2006, Scandinavian journal of immunology.

[45]  R. Adegbola,et al.  Reversion of the ELISPOT test after treatment in Gambian tuberculosis cases , 2006, BMC infectious diseases.

[46]  S. Arruda,et al.  Correlation between interleukin-10 and in situ necrosis and fibrosis suggests a role for interleukin-10 in the resolution of the granulomatous response of tuberculous pleurisy patients. , 2006, Microbes and infection.

[47]  F. Miedema,et al.  Expression of Chemokine Receptors CCR5 and CXCR4 on CD4+ T Cells and Plasma Chemokine Levels During Treatment of Active Tuberculosis in HIV-1-Coinfected Patients , 2005, Journal of acquired immune deficiency syndromes.

[48]  Alberto Mantovani,et al.  IFN-γ-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection , 2005 .

[49]  E. Capoluongo,et al.  Post-treatment changes of six cytokines in active pulmonary tuberculosis: differences between patients with stable or increased fibrosis. , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[50]  E. P. Moura,et al.  Pulmonary tuberculosis: evaluation of interferon-gamma levels as an immunological healing marker based on the response to the Bacillus Calmette-Guerin. , 2004, Memorias do Instituto Oswaldo Cruz.

[51]  J. Chang,et al.  Changes of Plasma Interleukin-1 Receptor Antagonist, Interleukin-8 and other Serologic Markers during Chemotherapy in Patients with Active Pulmonary Tuberculosis , 2003, The Korean journal of internal medicine.

[52]  Shenjie Tang,et al.  [Changes of proinflammatory cytokines and their receptors in serum from patients with pulmonary tuberculosis]. , 2002, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases.

[53]  J. Vekemans,et al.  Polarization of PPD-specific T-cell response of patients with tuberculosis from Th0 to Th1 profile after successful antimycobacterial therapy or in vitro conditioning with interferon-alpha or interleukin-12. , 2001, American journal of respiratory cell and molecular biology.

[54]  Jun-sang Kim,et al.  Depressed Interleukin-12 (IL-12), but not IL-18, Production in Response to a 30- or 32-Kilodalton Mycobacterial Antigen in Patients with Active Pulmonary Tuberculosis , 2000, Infection and Immunity.

[55]  S. Lawn,et al.  Elevated serum concentrations of soluble CD14 in HIV− and HIV+ patients with tuberculosis in Africa: prolonged elevation during anti‐tuberculosis treatment , 2000, Clinical and experimental immunology.

[56]  N. Juffermans,et al.  Serum concentrations of cytokines in patients with active tuberculosis (TB) and after treatment , 1999, Clinical and experimental immunology.

[57]  G. Kaplan,et al.  Selective increase in plasma tumor necrosis factor-alpha and concomitant clinical deterioration after initiating therapy in patients with severe tuberculosis. , 1998, The Journal of infectious diseases.

[58]  P. Kragsbjerg,et al.  Cytokine Responses in Patients with Pneumonia Caused by Chlamydia or Mycoplasma , 1998, Respiration.

[59]  T. van der Poll,et al.  Tumor necrosis factor and interleukin-1 inhibitors as markers of disease activity of tuberculosis. , 1998, American journal of respiratory and critical care medicine.

[60]  M. Torres,et al.  Cytokine Profiles for Peripheral Blood Lymphocytes from Patients with Active Pulmonary Tuberculosis and Healthy Household Contacts in Response to the 30-Kilodalton Antigen ofMycobacterium tuberculosis , 1998, Infection and Immunity.

[61]  M. Harboe,et al.  Longitudinal trends in serum levels of mycobacterial secretory (30 kD) and cytoplasmic (65 kD) antigens during chemotherapy of pulmonary tuberculosis patients. , 1998, Scandinavian journal of infectious diseases.

[62]  J. Hartley,et al.  Cytokine secretion in vivo and ex vivo following chemotherapy of Mycobacterium tuberculosis infection. , 1996, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[63]  V. Perumal,et al.  Association of increased mycobacterium growth inhibitory factor with antituberculous immunity. , 1991, The European respiratory journal.

[64]  A. Waage,et al.  ASSOCIATION BETWEEN TUMOUR NECROSIS FACTOR IN SERUM AND FATAL OUTCOME IN PATIENTS WITH MENINGOCOCCAL DISEASE , 1987, The Lancet.

[65]  A. Forrest,et al.  Letter: Procaine and malignant hyperthermia. , 1974, Lancet.

[66]  Germaine Greer,et al.  van Deventer H , 1968 .